Drugs / TARAGARESTRANT
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05339633 | Mar → Aug 2022 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05226338 | Oct → Dec 2021 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03810625 | Oct → Nov 2018 | breast cancer | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03471663 | Mar 2018 → Oct 2023 | breast cancer | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07336771 | Jan 2026 → Dec 2027 expected | breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06954961 | Sep 2022 → Nov 2026 expected | breast cancer | InventisBio Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TARAGARESTRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5087025 ↗ |
| Known as | D-0502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06954961 ↗ |
| Modality | Small molecule | — CHEMBL5087025 ↗ |
| Route | Oral | “oral tablets” NCT03471663 ↗ |